Amedisys' (AMED) "Outperform" Rating Reaffirmed at Royal Bank of Canada

Royal Bank of Canada restated their outperform rating on shares of Amedisys (NASDAQ:AMED - Free Report) in a research note released on Wednesday morning,Benzinga reports. Royal Bank of Canada currently has a $100.00 price target on the health services provider's stock.

Separately, Stephens restated an "equal weight" rating and issued a $101.00 price objective on shares of Amedisys in a research note on Tuesday, March 4th. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $100.75.

Amedisys Stock Up 0.1 %

NASDAQ AMED traded up $0.07 during trading on Wednesday, reaching $91.83. The company's stock had a trading volume of 152,425 shares, compared to its average volume of 399,405. The business has a 50-day moving average price of $92.14 and a 200-day moving average price of $91.86. Amedisys has a 1-year low of $82.15 and a 1-year high of $98.95. The stock has a market capitalization of $3.01 billion, a PE ratio of 36.44, a PEG ratio of 1.78 and a beta of 0.89. The company has a current ratio of 1.19, a quick ratio of 1.19 and a debt-to-equity ratio of 0.05.

Amedisys (NASDAQ:AMED - Get Free Report) last posted its earnings results on Wednesday, February 26th. The health services provider reported $0.96 earnings per share for the quarter, missing the consensus estimate of $1.05 by ($0.09). The company had revenue of $598.05 million for the quarter, compared to the consensus estimate of $602.38 million. Amedisys had a net margin of 3.57% and a return on equity of 12.20%. On average, research analysts forecast that Amedisys will post 4.4 earnings per share for the current fiscal year.

Institutional Trading of Amedisys

Institutional investors have recently modified their holdings of the company. MassMutual Private Wealth & Trust FSB boosted its stake in Amedisys by 56.1% during the first quarter. MassMutual Private Wealth & Trust FSB now owns 334 shares of the health services provider's stock worth $31,000 after buying an additional 120 shares in the last quarter. Blue Trust Inc. boosted its position in shares of Amedisys by 55.1% during the 4th quarter. Blue Trust Inc. now owns 349 shares of the health services provider's stock valued at $34,000 after acquiring an additional 124 shares in the last quarter. Fifth Third Bancorp raised its position in Amedisys by 68.1% in the first quarter. Fifth Third Bancorp now owns 348 shares of the health services provider's stock worth $32,000 after purchasing an additional 141 shares in the last quarter. Xponance Inc. lifted its stake in Amedisys by 3.5% during the fourth quarter. Xponance Inc. now owns 4,349 shares of the health services provider's stock worth $395,000 after purchasing an additional 148 shares during the period. Finally, Inspire Investing LLC boosted its holdings in Amedisys by 3.6% during the fourth quarter. Inspire Investing LLC now owns 4,405 shares of the health services provider's stock valued at $400,000 after purchasing an additional 155 shares in the last quarter. Institutional investors and hedge funds own 94.36% of the company's stock.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.